{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:27:08Z","timestamp":1767997628892,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T00:00:00Z","timestamp":1321315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>High\u2010dose chemotherapy with autologous hematopoietic cell transplant (auto\u2010HCT) has been shown to improve survival in patients with newly diagnosed multiple myeloma. However, the role of salvage auto\u2010HCT for relapsed patients, particularly in the era of novel therapeutics, is not well defined.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>The authors performed a retrospective analysis of all 44 myeloma patients (24 men, 20 women) who received a second auto\u2010HCT as salvage between January 3, 1992 and November 4, 2008 at The University of Texas MD Anderson Cancer Center.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Median interval between the first and salvage auto\u2010HCT was 30 months (range, 2\u201078 months). Median age at salvage HCT was 54 years (range, 38\u201073 years), and median number of salvage treatment regimens was 2 (range, 0\u20105). Eleven (25%) patients had high\u2010risk chromosomal abnormalities on conventional cytogenetic studies between diagnosis and salvage auto\u2010HCT. Ten patients (23%) experienced grade 3 or higher nonhematologic toxicity after the salvage auto\u2010HCT. One patient died within 100 days, for a treatment\u2010related mortality of 2%. Best responses after salvage chemotherapy + salvage auto\u2010HCT were as follows: complete response (CR) + near CR, 11%; partial response, 79%; overall response rate, 90%. Eighteen (41%) patients received post auto\u2010HCT maintenance therapy. Median follow\u2010up from salvage HCT was 41 months. Kaplan\u2010Meier estimates of median progression\u2010free survival (PFS) and overall survival (OS) from time of salvage auto\u2010HCT were 12.3 and 31.7 months, respectively. Median OS from the time of diagnosis was 75 months. In a fitted Bayesian multivariate model, shorter time to progression after first auto\u2010HCT, greater number of prior therapies, African American race, and immunoglobulin G subtype were significantly associated with worse OS.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>In selected myeloma patients, a second auto\u2010HCT for salvage therapy is well tolerated, with acceptable toxicity. The overall response rate and PFS are comparable to other salvage regimens. Cancer 2012;3549\u20133555. \u00a9 2011 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.26662","type":"journal-article","created":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T08:00:31Z","timestamp":1321430431000},"page":"3549-3555","source":"Crossref","is-referenced-by-count":67,"title":["Durable remission with salvage second autotransplants in patients with multiple myeloma"],"prefix":"10.1002","volume":"118","author":[{"given":"Nina","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fraz","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qaiser","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sijin","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Thall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Cancer Facts and Figures","year":"2006"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199607113350204"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0408"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn439"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-078022"},{"key":"e_1_2_6_8_2","first-page":"7","article-title":"Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy","volume":"16","author":"Tricot G","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21700"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.334"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701208"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M289"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_2_6_14_2","volume-title":"Introduction to the Theory of Nonparametric Statistics","author":"Randles R","year":"1979"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2397-2335.1922.tb00768.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_6_17_2","first-page":"163","article-title":"Evaluation of survival data and 2 new rank order statistics arising in its consideration","volume":"50","author":"Mantel N","year":"1966","journal-title":"Cancer Chemother Rep."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1214\/aos\/1176344136"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3121-7"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-300970"},{"key":"e_1_2_6_21_2","first-page":"141","article-title":"The role of second autografts in the management of myeloma at first relapse","volume":"91","author":"Alvares CL","year":"2006","journal-title":"Haematologica."},{"key":"e_1_2_6_22_2","first-page":"110","article-title":"Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma: improved outcomes in patients with longer disease free interval after first ASCT [abstract]","author":"Mikhael JR","year":"2007","journal-title":"Blood."},{"key":"e_1_2_6_23_2","first-page":"25","article-title":"Outcome after second stem cell transplantation for relapsed multiple myeloma [abstract]","author":"Simpson L","year":"2007","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903085936"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-04-0632"},{"key":"e_1_2_6_26_2","unstructured":"ShahN WeberD AlexanianR et al.Survival disparities between African\u2010American and Caucasian patients with multiple myeloma are blunted in the era of novel therapeutics and autologous stem cell transplantation. Paper presented at: American Society of Hematology Annual Meeting; December 5\u20108 2009; New Orleans La."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703093"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070596"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05188.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.5460"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0501-0"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11228"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06656.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.2372"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.26662","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.26662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:51:58Z","timestamp":1760280718000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.26662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,15]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2012,7,15]]}},"alternative-id":["10.1002\/cncr.26662"],"URL":"https:\/\/doi.org\/10.1002\/cncr.26662","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,15]]}}}